Concord Biotech Ltd.
Fundamentals
- Market cap
- ₹13,455 cr
- P/E
- 51.57×
- ROE
- 20.50%
- Debt / equity
- 0.00
- Div yield
- 0.59%
- 52-week range
- 987.00 — 1980.00
Concord Biotech Ltd.
Latest quarter · Mar 2026
Strength & growth
The timeline — 7 notes on Concord Biotech Ltd.
June 2026
- 12 Jun 26 · 1:31 PM IST Brief Brief · Mid cap
Concord Biotech clears ANVISA hurdle, opens Brazil API market
ANVISA inspection at Limbasi facility passed; exports to Brazil now permitted. No revenue estimate provided. Concord's trailing revenue is ₹1,054 cr.
- 10 Jun 26 · 10:10 AM IST Alert Alert · Mid cap
Concord Biotech lands USFDA okay for Tofacitinib, a $500M U.S. opportunity
The approval opens a market nearly four times the size of Concord's annual revenue.
- 05 Jun 26 · 6:37 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech expects growth to return in FY27 after profit dropped 30%
The API maker's net profit fell to ₹259 crore in FY26 as geopolitical disruptions hurt sales. Management now guides for a double-digit revenue rebound in the first half of FY27.
- 02 Jun 26 · 4:36 PM IST Lead Lead · Mid cap
Concord Biotech wins USFDA nod for generic transplant drug
The approval unlocks a US$30 million U.S. market for the immunosuppressant Mycophenolate Mofetil, equal to about a quarter of Concord's annual revenue.
May 2026
- 29 May 26 · 8:39 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech's profit falls 30% on a 12% revenue slide
Full-year audited numbers show margin pressure, but the board still proposes a dividend of ₹7.55 per share.
- 29 May 26 · 8:17 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech profit drops 30% on 11% revenue fall
FY26 net profit fell to ₹259.23 crore as total income contracted, ending a growth streak. The board has proposed a ₹7.55 per share dividend.
- 29 May 26 · 7:53 PM IST Brief Brief · Earnings · Mid cap
Concord Biotech profit falls 30% as revenue shrinks in FY26
Consolidated net profit dropped to ₹259.22 crore from ₹371.64 crore. Revenue from operations contracted 12%.